OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination

dc.contributor.authorBaietti, Maria Francesca
dc.contributor.authorSimicek, Michal
dc.contributor.authorAbbasi Asbagh, Layka
dc.contributor.authorRadaelli, Enrico
dc.contributor.authorLievens, Sam
dc.contributor.authorCrowther, Jonathan
dc.contributor.authorSteklov, Mikhail
dc.contributor.authorAushev, Vasily N.
dc.contributor.authorMartínez García, David
dc.contributor.authorTavernier, Jan
dc.contributor.authorSablina, Anna A.
dc.date.accessioned2019-05-24T16:32:29Z
dc.date.available2019-05-24T16:32:29Z
dc.date.issued2016-02-08
dc.date.updated2019-05-24T16:32:29Z
dc.description.abstractActivation of the RAS oncogenic pathway, frequently ensuing from mutations in RAS genes, is a common event in human cancer. Recent reports demonstrate that reversible ubiquitination of RAS GTPases dramatically affects their activity, suggesting that enzymes involved in regulating RAS ubiquitination may contribute to malignant transformation. Here, we identified the de-ubiquitinase OTUB1 as a negative regulator of RAS mono- and di-ubiquitination. OTUB1 inhibits RAS ubiquitination independently of its catalytic activity resulting in sequestration of RAS on the plasma membrane. OTUB1 promotes RAS activation and tumorigenesis in wild-type RAS cells. An increase of OTUB1 expression is commonly observed in non-small-cell lung carcinomas harboring wild-type KRAS and is associated with increased levels of ERK1/2 phosphorylation, high Ki67 score, and poorer patient survival. Our results strongly indicate that dysregulation of RAS ubiquitination represents an alternative mechanism of RAS activation during lung cancer development
dc.format.extent16 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec676948
dc.identifier.issn1757-4676
dc.identifier.pmid26881969
dc.identifier.urihttps://hdl.handle.net/2445/133844
dc.language.isoeng
dc.publisherEMBO Press
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.15252/emmm.201505972
dc.relation.ispartofEMBO Molecular Medicine, 2016, vol. 8, num. 3, p. 288-303
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/340941/EU//CYRE
dc.relation.urihttps://doi.org/10.15252/emmm.201505972
dc.rightscc-by (c) Baietti, Maria Francesca et al., 2016
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationCisteïna
dc.subject.classificationPèptids
dc.subject.classificationMetabolisme
dc.subject.classificationPatologia
dc.subject.classificationCàncer de pulmó
dc.subject.classificationProteïnes ras
dc.subject.otherCysteine
dc.subject.otherPeptides
dc.subject.otherMetabolism
dc.subject.otherPathology
dc.subject.otherLung cancer
dc.subject.otherRas proteins
dc.titleOTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
676948.pdf
Mida:
1.45 MB
Format:
Adobe Portable Document Format